In Brief:
For refractory cancer pain patients with intrathecal drug delivery treatment, hydromorphone shows noninferiority in analgesic efficacy to morphine, however, at different doses and that the doses of morphine tended to increase, whereas those of hydromorphone decreased over time. Intrathecal hydromorphone also offers an advantage over morphine in controlling breakthrough pain.